Study of DS-1123a in Advanced Solid Tumours
Study of DS-1123a in Advanced Solid Tumours
This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of
 DS-1123a in Japanese subjects with advanced solid tumors.
Inclusion Criteria:

 -  Advanced solid tumor that is refractory to standard treatment, or for which no
 standard treatment is available.

 -  Eastern Cooperative Oncology Group performance status (PS) of 0 or 1.

 Exclusion Criteria:

 -  Have any of the following concomitant disease or had the history of having following
 disease within 6 months before enrollment:

 • Cardiac failure (NYHA ≥ ClassIII), myocardial infarction, cerebral infarction,
 unstable angina, arrhythmia requiring treatment, coronary-artery/peripheral artery
 bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deep-vein
 thrombosis or clinically severe thromboembolic event, or clinically severe pulmonary
 disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug
 induced pneumonia),

 -  Severe or uncontrolled concomitant disease.

 -  Clinically active brain metastases defined as symptomatic or requiring treatment.